securities fraud

Kyndryl Holdings faces securities fraud lawsuit over internal control failures and executive departures. Stock crashed 55% after delayed 10-Q filing disclosure.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Kahn Swick & Foti, LLC filed class action lawsuits against Navan, Kyndryl, and Ultragenyx for alleged securities disclosure violations. Lead plaintiff applications due April 24, 2026.

CoreWeave faces class action securities fraud lawsuit alleging overstatement of capacity and understatement of supplier risks between March-December 2025. Lead plaintiff applications due March 13, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Ardent Health faces securities fraud lawsuit over alleged failure to disclose collections problems. Stock fell 33% after November revelation of $43M revenue cut and $57.5M EBITDA guidance reduction.

BellRing Brands faces securities fraud lawsuit after 52% stock decline tied to undisclosed inventory issues and weak guidance, with investor deadline March 23, 2026.

Varonis faces class action for allegedly misrepresenting ARR growth sustainability, triggering 48.7% stock collapse. Lead plaintiff deadline: March 9, 2026.

Varonis faces class action lawsuit over undisclosed business challenges. Stock crashed 48.7% after disappointing guidance. Investors must act by March 9, 2026.

KDDI delays earnings amid internal investigation, triggering 11.4% ADR decline and spurring Rosen Law Firm class action lawsuit.

Lufax Holding Ltd ($LU) shares dropped 13.8% on January 27 after announcing auditor removal and potential 2024 annual report delays. Securities investigation launched.

Navan faces class action lawsuit alleging October 2025 IPO documents omitted planned 39% sales-marketing spending increase. Stock down 63% from $25 IPO price to $9.20.

Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.

Pomerantz Law Firm investigates $FSK over potential securities fraud following steep dividend cut and $440M non-accrual investment disclosure.

Class action lawsuit filed against Apollo Global Management ($APO) over undisclosed Epstein discussions by CEO Marc Rowan. Investors can claim lead plaintiff status until May 1, 2026.

$PYPL faces class action lawsuit over allegedly false revenue projections. Stock plunged 20% after disappointing earnings and guidance withdrawal in February 2026.

PROCEPT BioRobotics faces securities fraud investigation after missing Q4 2025 revenue and slashing 2026 guidance by $20-40 million, prompting 15% stock decline.

Walker & Dunlop crashed 19% after reporting adjusted EPS 81% below consensus. Law firm investigates potential securities fraud following February 26 earnings miss.

Helen of Troy faces securities probe after October earnings miss; net sales fell 8.9%, stock dropped 25% to $20.71.

Pomerantz LLP investigates $UPST over Model 22 underwriting system reducing borrower approvals, triggering sharp stock decline following November disclosure.